Regeneron?s Q1 2025: A Strong Dose of Growth Amidst Regulatory Excitement

April 29, 2025 | By Matt Levine Inspired Finance

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has just dropped its first quarter earnings like a new blockbuster drug, and the numbers are making quite the splash. The company reported revenues of $3.0 billion, accompanied by a GAAP diluted EPS of $7.27, which seems to have surpassed the EPS consensus among analysts, setting the stage for an earnings surprise that investors are surely toasting to.

Revenue Highlights: A Prescription for Success

With a revenue forecast that?s clearly on the upswing, Regeneron?s first quarter earnings reflect a notable 19% increase in global net sales of Dupixent, which hit $3.67 billion, as recorded by Sanofi. That?s a hefty dose of growth compared to last year, and it?s not just the sales figures that are impressive; the excitement doesn?t stop there.

Meanwhile, EYLEA HD U.S. net sales rose by 54% to $307 million, though total sales for EYLEA saw a 26% decrease to $1.04 billion. This mix of numbers indicates both a shift in market dynamics and the potential for Regeneron to adapt its strategies effectively.

Regulatory Wins and Future Prospects

On the regulatory front, Regeneron is not just sitting back and counting its cash. The company has received FDA approval for Dupixent in treating chronic spontaneous urticaria (CSU) in the U.S. and chronic obstructive pulmonary disease (COPD) in Japan. This expansion of indications could not only bolster sales but also further entrench Dupixent as a go-to treatment, thereby enhancing its market presence.

There?s more: the FDA has accepted for priority review the sBLA for EYLEA HD, which suggests that Regeneron is firmly in the regulatory fast lane. With updates on other FDA submissions also on the horizon, it appears that the company is gearing up for a significant year ahead.

Investments in the Future: Building a Strong Foundation

In an impressive show of commitment, Regeneron announced ongoing and planned investments exceeding $7 billion in infrastructure and manufacturing in New York and North Carolina. This ambitious initiative is not just about boosting production; it?s about reinforcing the company?s position as a leader in innovation and patient care.

As Leonard S. Schleifer, M.D., Ph.D., CEO of Regeneron, puts it, ?Regeneron has one of the most exciting pipelines in the industry." With a focus on fulfilling the promise of this pipeline, investors might want to keep a close watch, as the potential for future earnings surprises looms large.

Conclusion: A Dose of Optimism for Investors

In summary, Regeneron's Q1 results are a clear indication that the company is not only thriving but also strategically positioning itself for future growth. The combination of strong earnings, regulatory advancements, and significant investments suggests that REGN is on a promising path. For investors, the prescription seems clear: keep this stock on your radar. It?s shaping up to be a thrilling ride in the biotech sector this year.